Treatment outcomes of multidrug-resistant tuberculosis in Switzerland

Swiss Medical Weekly

Volumn 144, Issue , 2014, Pages

  Helbling, Peter ^a   Altpeter, Ekkehardt ^a   Egger, Jean Marie ^b   Zellweger, Jean Pierre ^b  

^a FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

^b TB Competence Centre   (Switzerland)

Author keywords

Antituberculosis drug resistance; Epidemiology; MDR; Multidrug resistance; Switzerland; Treatment outcomes; Treatment results; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AFRICA; ARTICLE; ASIA; ASYLUM SEEKER; BACTERIAL STRAIN; CAUSE OF DEATH; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT SATISFACTION; REFUGEE; SWISS; SWITZERLAND; TREATMENT DURATION; TREATMENT OUTCOME; USSR; CLASSIFICATION; DRUG EFFECTS; FOLLOW UP; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MOLECULAR TYPING; MYCOBACTERIUM TUBERCULOSIS; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR TYPING; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; SWITZERLAND; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84929056205     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2014.14053     Document Type: Article

References (31)

1. World Health Organization. Global Tuberculosis Report 2013. WHO/ HTM/TB/2013.11.
2. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ. 2012;90(2):111-119D.
3. Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366(23):2161-70.
4. Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, Hoffner S, et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ. 2013;91(1):36-45.
5. Office fédéral de la santé publique. La tuberculose en Suisse 2005-2011. Bulletin OFSP 2013;21:343-53.
6. Minion J, Gallant V, Wolfe J, Jamieson F, Long R. Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics. PLoS One. 2013;8(1):e53466.
7. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10(9):621-9.
8. Helbling P, Medinger C, Altpeter E, Raeber PA, Beeli D, Zellweger JP. Outcome of treatment of pulmonary tuberculosis in Switzerland in 1996. Swiss Med Wkly. 2002;132(35-36):517-22.
9. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300.
10. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(3):153-61.
11. Johnston JC, Shahidi NC, Sadatsafavi M, FitzGerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4(9):e6914.
12. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9(6):640-5.
13. Caminero JA, ed. Guidelines for clinical and operational management of drug-resistant tuberculosis. Paris, France: International Union Against Tuberculosis and Lung Disease; 2013.
14. Bottger EC. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect. 2011;17(8):1128-34.
15. World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision. WHO/HTM/TB/2013.2.
16. Gimmi R, Pfyffer GE, Brändli O. Tuberculose multirésistante - guérissable en Suisse. Forum Med Suisse. 2003;4:80-90.
17. European Centre for Disease Prevention and Control. Tuberculosis surveillance and monitoring in Europe 2013. European Centre for Disease Prevention and Control; Stockholm, 2013.
18. Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, Chen MP, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J. 2010;36(3):584-93.
19. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684-92.
20. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. WHO/HTM/TB/ 2011.6.
21. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508-18.
22. Yew WW, Lange C, Leung CC. Treatment of tuberculosis: update 2010. Eur Respir J. 2011;37(2):441-62.
23. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10 Suppl 2):S231-S279.
24. Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis. 2012;16(6):724-32.
25. Leung EC, Yew WW, Leung CC, Leung WM, Tam CM. Shorter treatment duration for selected patients with multidrug-resistant tuberculosis. Eur Respir J. 2011;38(1):227-30.
26. Cox HS, Niemann S, Ismailov G, Doshetov D, Orozco JD, Blok L, et al. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin Infect Dis. 2007;44(11):1421-7.
27. van der Werf MJ, Langendam MW, Huitric E, Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J. 2012;39(6):1511-9.
28. Royce S, Falzon D, Van WC, Dara M, Hyder K, Hopewell P, et al. Multidrug resistance in new tuberculosis patients: burden and implications. Int J Tuberc Lung Dis. 2013;17(4):511-3.
29. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151-60.
30. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56(6):3271-6.
31. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, et al. Early bactericidal activity of delamanid (OPC-67683) in smearpositive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011;15(7):949-54.